Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 479

Similar articles for PubMed (Select 16169683)

1.

Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.

Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1463-8. Epub 2005 Sep 19.

PMID:
16169683
2.

Image-guided Intensity-modulated Radiotherapy for Prostate Cancer Employing Hypofractionation and Simultaneous Integrated Boost: Results of a Consecutive Case Series with Focus on Erectile Function.

Girelli G, Franco P, Sciacero P, Cante D, Borca VC, Pasquino M, Annoscia S, Tofani S, LA Porta MR, Ricardi U.

Anticancer Res. 2015 Jul;35(7):4177-82.

PMID:
26124375
3.
4.

Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales.

Ferrera G, Mortellaro G, Mannino M, Caminiti G, Spera A, Figlia V, Iacoviello G, Di Paola G, Mazzola R, Lo Casto A, Alongi F, Pappalardo MP, Lagalla R.

Radiol Med. 2015 May 24. [Epub ahead of print]

PMID:
26002724
5.

High-dose rate brachytherapy boost for prostate cancer: Outcomes and genitourinary toxicity.

Bece A, Patanjali N, Jackson M, Whitaker M, Hruby G.

Brachytherapy. 2015 May 11. pii: S1538-4721(15)00461-4. doi: 10.1016/j.brachy.2015.04.004. [Epub ahead of print]

PMID:
25976294
6.

Hypofractionated palliative radiotherapy for bladder cancer.

Dirix P, Vingerhoedt S, Joniau S, Van Cleynenbreugel B, Haustermans K.

Support Care Cancer. 2015 May 16. [Epub ahead of print]

PMID:
25975677
7.

Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.

Kole TP, Tong M, Wu B, Lei S, Obayomi-Davies O, Chen LN, Suy S, Dritschilo A, Yorke E, Collins SP.

Acta Oncol. 2015 May 14:1-7. [Epub ahead of print]

PMID:
25972264
8.

Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.

Tramacere F, Arcangeli S, Pignatelli A, Castagna R, Portaluri M.

Anticancer Res. 2015 May;35(5):3049-54.

PMID:
25964594
9.

Long-Term Efficacy and Toxicity of Low-Dose-Rate (125)I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.

Kittel JA, Reddy CA, Smith KL, Stephans KL, Tendulkar RD, Ulchaker J, Angermeier K, Campbell S, Stephenson A, Klein EA, Wilkinson DA, Ciezki JP.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):884-93. doi: 10.1016/j.ijrobp.2015.02.047. Epub 2015 May 8.

PMID:
25962627
10.

Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy.

McDonald AM, Baker CB, Popple RA, Cardan RA, Fiveash JB.

Pract Radiat Oncol. 2015 Apr 6. pii: S1879-8500(15)00080-6. doi: 10.1016/j.prro.2015.02.010. [Epub ahead of print]

PMID:
25858771
11.

Prostate hypofractionated radiation therapy with injection of hyaluronic acid: acute toxicities in a phase 2 study.

Chapet O, Decullier E, Bin S, Faix A, Ruffion A, Jalade P, Fenoglietto P, Udrescu C, Enachescu C, Azria D.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):730-6. doi: 10.1016/j.ijrobp.2014.11.027.

PMID:
25752385
12.

Prostate cancer: Hypofractionation not associated with reduced toxicity.

Kelsey R.

Nat Rev Urol. 2015 Mar;12(3):126. doi: 10.1038/nrurol.2015.27. Epub 2015 Feb 17. No abstract available.

PMID:
25687269
13.

Hypofractionated radiotherapy in prostate cancer.

Dearnaley DP.

Lancet Oncol. 2015 Mar;16(3):237-8. doi: 10.1016/S1470-2045(15)70021-5. Epub 2015 Feb 3. No abstract available. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105.

PMID:
25656288
14.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L.

Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105.

PMID:
25656287
15.

Anterior-oriented proton beams for prostate cancer: A multi-institutional experience.

Cuaron JJ, Harris AA, Chon B, Tsai H, Larson G, Hartsell WF, Hug E, Cahlon O.

Acta Oncol. 2015 Jun;54(6):868-74. doi: 10.3109/0284186X.2014.986288. Epub 2015 Jan 16.

PMID:
25591937
16.

Radiation therapy for clinically localized prostate cancer: Long-term results of 469 patients from a single institution in the era of dose escalation.

Surapaneni A, Schwartz D, Nwokedi E, Rineer J, Rotman M, Schreiber D.

J Cancer Res Ther. 2014 Oct-Dec;10(4):951-6. doi: 10.4103/0973-1482.138096.

17.

Three-dimensional ultrasound-based image-guided hypofractionated radiotherapy for intermediate-risk prostate cancer: results of a consecutive case series.

Ricardi U, Franco P, Munoz F, Levis M, Fiandra C, Guarneri A, Moretto F, Bartoncini S, Arcadipane F, Badellino S, Piva C, Trino E, Ruggieri A, Filippi AR, Ragona R.

Cancer Invest. 2015 Mar;33(2):23-8. doi: 10.3109/07357907.2014.988343. Epub 2014 Dec 19.

PMID:
25526035
18.

Assessment of risk of late rectal bleeding for patients with prostate cancer started on anticoagulation before or after radiation treatment.

Schreiber D, Chen SC, Rineer J, Worth M, Telivala T, Schwartz D.

Anticancer Res. 2014 Dec;34(12):7367-72.

PMID:
25503174
20.

Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy.

Fiorino C, Cozzarini C, Rancati T, Briganti A, Cattaneo GM, Mangili P, Di Muzio NG, Calandrino R.

Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1250-7. doi: 10.1016/j.ijrobp.2014.08.347. Epub 2014 Oct 13.

PMID:
25442349
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk